Arcus Biosciences, Inc. , a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that ...

California Democratic Rep. Jared Huffman protested the National Prayer Breakfast Thursday, claiming it violates the ...

TD Cowen raised the firm’s price target on Gilead (GILD) to $100 from $95 and keeps a Buy rating on the shares. The firm said they posted a ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...

Gilead Sciences Inc. hit a new 52-week high, surpassing its previous peak of $99.45, which the company achieved on February ...

This was the stock's second consecutive day of losses.

Today's Research Daily features new research reports on 16 major stocks, including Uber Technologies, Inc. (UBER), Comcast Corp. (CMCSA) and Gilead Sciences, Inc. (GILD), as well as a micro-cap ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine. However, Ben Hargreaves finds that the company’s ...

The head of the U.N. AIDS agency says the number of new HIV infections could jump more than six times by 2029 if American support of the biggest AIDS program is dropped.

Latonia Wilkins knows she needs to be on PrEP due to her non-monogamous lifestyle. But the 52-year-old Atlanta mother has faced repeated challenges getting the lifesaving drug that can prevent new HIV ...